|
1
|
Craig AJ, von Felden J, Garcia-Lezana T,
Sarcognato S and Villanueva A: Tumour evolution in hepatocellular
carcinoma. Nat Rev Gastroenterol Hepatol. 17:139–152. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lohitesh K, Chowdhury R and Mukherjee S:
Resistance a major hindrance to chemotherapy in hepatocellular
carcinoma: An insight. Cancer Cell Int. 18:442018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meena AS, Sharma A, Kumari R, Mohammad N,
Singh SV and Bhat MK: Inherent and acquired resistance to
paclitaxel in hepatocellular carcinoma: Molecular events involved.
PLoS One. 8:e615242013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vasuri F, Visani M, Acquaviva G, Brand T,
Fiorentino M, Pession A, Tallini G, D'Errico A and de Biase D: Role
of microRNAs in the main molecular pathways of hepatocellular
carcinoma. World J Gastroenterol. 24:2647–2660. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yan H, Wang S, Yu H, Zhu J and Chen C:
Molecular pathways and functional analysis of miRNA expression
associated with paclitaxel-induced apoptosis in hepatocellular
carcinoma cells. Pharmacology. 92:167–174. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang X, Qin J and Lu S: Up-regulation of
miR-877 induced by paclitaxel inhibits hepatocellular carcinoma
cell proliferation though targeting FOXM1. Int J Clin Exp Pathol.
8:1515–1524. 2015.PubMed/NCBI
|
|
8
|
Chen Y, Feng F, Gao X, Wang C, Sun H,
Zhang C, Zeng Z, Lu Y, An L, Qu J, et al: MiRNA153 Reduces Effects
of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in
HCC Cells. Curr Cancer Drug Targets. 15:176–187. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xie C, Chen B, Wu B, Guo J and Cao Y:
LncRNA TUG1 promotes cell proliferation and suppresses apoptosis in
osteosarcoma by regulating miR-212-3p/FOXA1 axis. Biomed
Pharmacother. 97:1645–1653. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He X and Fan S: hsa-miR-212 modulates the
radiosensitivity of glioma cells by targeting BRCA1. Oncol Rep.
39:977–984. 2018.PubMed/NCBI
|
|
11
|
Tu H, Wei G, Cai Q, Chen X, Sun Z, Cheng
C, Zhang L, Feng Y, Zhou H, Zhou B, et al: MicroRNA-212 inhibits
hepatocellular carcinoma cell proliferation and induces apoptosis
by targeting FOXA1. Onco Targets Ther. 8:2227–2235. 2015.PubMed/NCBI
|
|
12
|
Shen S, Lin Y, Yuan X, Shen L, Chen J,
Chen L, Qin L and Shen B: Biomarker MicroRNAs for Diagnosis,
Prognosis and Treatment of Hepatocellular Carcinoma: A Functional
Survey and Comparison. Sci Rep. 6:383112016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hegarty SV, Sullivan AM and O'Keeffe GW:
Zeb2: A multifunctional regulator of nervous system development.
Prog Neurobiol. 132:81–95. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han ML, Zhao YF, Tan CH, Xiong YJ, Wang
WJ, Wu F, Fei Y, Wang L and Liang ZQ: Cathepsin L
upregulation-induced EMT phenotype is associated with the
acquisition of cisplatin or paclitaxel resistance in A549 cells.
Acta Pharmacol Sin. 37:1606–1622. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li C, Lu L, Feng B, Zhang K, Han S, Hou D,
Chen L, Chu X and Wang R: The lincRNA-ROR/miR-145 axis promotes
invasion and metastasis in hepatocellular carcinoma via induction
of epithelial-mesenchymal transition by targeting ZEB2. Sci Rep.
7:46372017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu D, Wu S, Hu C, Chen Z, Wang H, Fan F,
Qin Y, Wang C, Sun H, Leng X, et al: Folate-targeted polymersomes
loaded with both paclitaxel and doxorubicin for the combination
chemotherapy of hepatocellular carcinoma. Acta Biomater.
58:399–412. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen J, Jin R, Zhao J, Liu J, Ying H, Yan
H, Zhou S, Liang Y, Huang D, Liang X, et al: Potential molecular,
cellular and microenvironmental mechanism of sorafenib resistance
in hepatocellular carcinoma. Cancer Lett. 367:1–11. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mir N, Jayachandran A, Dhungel B, Shrestha
R and Steel JC: Epithelial-to-Mesenchymal Transition: A Mediator of
Sorafenib Resistance in Advanced Hepatocellular Carcinoma. Curr
Cancer Drug Targets. 17:698–706. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao YF, Han ML, Xiong YJ, Wang L, Fei Y,
Shen X, Zhu Y and Liang ZQ: A miRNA-200c/cathepsin L feedback loop
determines paclitaxel resistance in human lung cancer A549 cells in
vitro through regulating epithelial-mesenchymal transition. Acta
Pharmacol Sin. 39:1034–1047. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Wang W, Wang Y, Huang X, Zhang Z,
Chen B, Xie W, Li S, Shen S and Peng B: NEK2 promotes
hepatocellular carcinoma migration and invasion through modulation
of the epithelial-mesenchymal transition. Oncol Rep. 39:1023–1033.
2018.PubMed/NCBI
|
|
22
|
Kim JJ, Yin B, Christudass CS, Terada N,
Rajagopalan K, Fabry B, Lee DY, Shiraishi T, Getzenberg RH, Veltri
RW, et al: Acquisition of paclitaxel resistance is associated with
a more aggressive and invasive phenotype in prostate cancer. J Cell
Biochem. 114:1286–1293. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li H, Zhang P, Sun X, Sun Y, Shi C, Liu H
and Liu X: MicroRNA-181a regulates epithelial-mesenchymal
transition by targeting PTEN in drug-resistant lung adenocarcinoma
cells. Int J Oncol. 47:1379–1392. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hou P, Kang Y and Luo J: Hypoxia-mediated
miR-212-3p downregulation enhances progression of intrahepatic
cholangiocarcinoma through upregulation of Rab1a. Cancer Biol Ther.
19:984–993. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Y, Zhang XL, Li XF, Tang YC and Zhao
X: miR-212-3p reduced proliferation, and promoted apoptosis of
fibroblast-like synoviocytes via down-regulating SOX5 in rheumatoid
arthritis. Eur Rev Med Pharmacol Sci. 22:461–471. 2018.PubMed/NCBI
|
|
26
|
Liu H, Li C, Shen C, Yin F, Wang K, Liu Y,
Zheng B, Zhang W, Hou X, Chen X, et al: MiR-212-3p inhibits
glioblastoma cell proliferation by targeting SGK3. J Neurooncol.
122:431–439. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qiu G, Lin Y, Zhang H and Wu D: miR-139-5p
inhibits epithelial-mesenchymal transition, migration and invasion
of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2.
Biochem Biophys Res Commun. 463:315–321. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Duan X, Fu Z, Gao L, Zhou J, Deng X, Luo
X, Fang W and Luo R: Direct interaction between miR-203 and ZEB2
suppresses epithelial-mesenchymal transition signaling and reduces
lung adenocarcinoma chemoresistance. Acta Biochim Biophys Sin
(Shanghai). 48:1042–1049. 2016. View Article : Google Scholar : PubMed/NCBI
|
